Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Celastrus Paniculatus | Modafinil | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 500-1000 mg/day of seed extract (standardized to >8% polyphenols) or 10-15 seeds daily (traditional Ayurvedic dosing, escalated from 1 seed/day) | 100-200 mg once daily (for educational context only — prescription medication in most jurisdictions) |
| Timing | Morning, with or without food. Traditional practice involves gradual dose escalation starting from 1 seed daily, increasing by 1 seed per day up to 10-15. | Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours. |
| Cycle Duration | Traditionally used in 30-60 day courses. No established cycling protocol from clinical data. | Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use). |
| Evidence Level | animal_plus_anecdotal | strong_human |
Seed oil contains sesquiterpenes, alkaloids (celastrine, paniculatin), and polyunsaturated fatty acids that demonstrate dose-dependent cholinergic activity by inhibiting acetylcholinesterase (AChE) and increasing acetylcholine levels in hippocampal and cortical regions. Provides neuroprotection against oxidative stress through elevation of glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD). Seed extracts attenuate hydrogen peroxide- and glutamate-induced excitotoxic injury in neuronal cells, and exhibit anti-inflammatory and anxiolytic properties.
500-1000 mg/day of seed extract (standardized to >8% polyphenols) or 10-15 seeds daily (traditional Ayurvedic dosing, escalated from 1 seed/day)
Morning, with or without food. Traditional practice involves gradual dose escalation starting from 1 seed daily, increasing by 1 seed per day up to 10-15.
Traditionally used in 30-60 day courses. No established cycling protocol from clinical data.
Atypical eugeroic (wakefulness-promoting agent) that primarily inhibits the dopamine transporter (DAT), increasing extracellular dopamine in the prefrontal cortex and nucleus accumbens. This primary action cascades through multiple systems: indirect activation of orexinergic neurons in the lateral hypothalamus via potentiation of glutamatergic transmission; downstream stimulation of histaminergic neurons in the tuberomammillary nucleus (via orexin-mediated disinhibition of GABAergic inputs); and enhancement of norepinephrine release in the locus coeruleus. The net effect is broad-spectrum arousal without the peripheral sympathomimetic effects of classical stimulants.
100-200 mg once daily (for educational context only — prescription medication in most jurisdictions)
Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours.
Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →